ReviewPaediatric drugs2026
Adolescents' and Young Adults' Adherence to Medication During the Transition to Adult Healthcare: A Developmentally Appropriate Framework for Optimising Adherence-Promoting Interventions.
Review in Paediatric drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CRD-guided step-up care for pediatric dust mite allergy: A systematic review of evidence gaps and global disparities (2014-2025).The World Allergy Organization journal · 2026Review
- Medication adherence in adolescents: physiological, psychosocial, and clinical perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For adolescents and young adults (AYA) with any health condition, it is important that they learn to manage their condition and healthcare as they transition into adulthood. For AYA with childhood-onset long-term conditions, this is also fundamental for a successful transition from child- to adult-centred services, as this period is associated with a decline in important health behaviours, such as medication adherence, which in turn are associated with poorer clinical outcomes and increased mortality. Current evidence suggests that, even though AYA are at higher risk for non-adherence than other age groups, existing interventions are less likely to be effective, or may bring about more modest benefits, for AYA compared with younger children and older adults. There is still a need for novel, innovative approaches to medication adherence that can help better meet the unique needs of AYA groups. We suggest that developmentally informed and developmentally tailored approaches may offer a promising avenue to achieve this. The most widely reported AYA adherence issues are deeply intertwined with the different stages of AYA biopsychosocial development and, therefore, AYA development can be understood as a common thread underlying AYA adherence issues. Ensuring that AYA adherence-promoting interventions are relative to an ongoing developmental assessment is crucial, not only to better meet AYA needs as they gradually prepare for their transfer to adult care, but also to continue to do so in the often forgotten third phase of transitional care (i.e. following transfer) well into their late adolescence and young adulthood.
Indexed as
Identifiers
41182659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.